[Use of pefloxacin in the treatment of patients with purulent wounds of soft tissues].
Pefloxacin was used in the treatment of 25 patients with wound infection in a dose of 400 mg orally twice a day for 10-12 days. As the monotherapy it was applied to 15 patients. 7 patients with clinical signs of non-clostridial anaerobic infection were treated with pefloxacin in combination with intravenous metronidazole. Pefloxacin was highly efficient in 96 per cent of the cases with extensive posttraumatic purulent wounds with and without bone affection, acute purulent wounds of the soft tissue, purulent wounds of the soft tissues in diabetic patients, trophic or decubitus ulcer. 266 clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Proteus mirabilis, Enterobacter spp. and Acinetobacter spp, were tested and 75 to 100 per cent of them was shown to be susceptible to pefloxacin and ciprofloxacin. At the same time the isolates of Pseudomonas aeruginosa and Klebsiella spp. were more susceptible to ciprofloxacin. The pathogen eradication and eradication with superinfection in the cases treated with pefloxacin amounted to 92 per cent. The drug tolerance was good. No clinically significant adverse events were recorded.
Blatun
L A
LA
A.V. Vishnevsky Institute of Surgery, Russian Academy of Medical Sciences, Moscow.
Puchkova
L S
LS
Navashin
P S
PS
Iakovlev
V P
VP
Svetykhin
A M
AM
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015366:Pefloxacin / Q000627:therapeutic use*; D018461:Soft Tissue Infections / Q000188:drug therapy*; D014946:Wound Infection / Q000188:drug therapy*
D000890:Anti-Infective Agents; D015366:Pefloxacin